01—Abstract
Summary
Summary of the 10-Q filed October 30, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc.'s third-quarter 2020 Form 10-Q filing highlights the company's significant efforts and investments in developing its mRNA-1273 vaccine candidate for COVID-19.
The report emphasizes the ongoing clinical trials and manufacturing scale-up for this candidate, which is considered a potential first commercial product. Moderna disclosed substantial cash and investments, indicating a strong liquidity position sufficient to fund operations for at least the next 12 months. However, the company also noted its history of significant losses and anticipates continued losses for the foreseeable future, relying on future capital raises through equity or debt offerings to fund its extensive research and development pipeline.
The filing also details numerous risks associated with the development and commercialization of novel medicines, particularly those based on mRNA technology. These risks include potential delays in clinical trials due to the ongoing COVID-19 pandemic, manufacturing challenges, regulatory hurdles, and intense competition.
Moderna's reliance on third-party manufacturers and strategic alliances is also a key consideration. The company is actively preparing for the potential commercialization of mRNA-1273, investing in sales and marketing capabilities, despite lacking prior experience in these areas.
02—Key points
Key Highlights
- Moderna's primary focus remains on the development of its mRNA-1273 vaccine candidate for COVID-19, with significant progress in clinical trials and manufacturing scale-up.
- The company reported approximately $3.97 billion in cash, cash equivalents, and investments as of September 30, 2020, expecting this to fund operations for at least the next 12 months.
- Despite a strong liquidity position, Moderna has a history of significant net losses and anticipates continuing to incur losses for the foreseeable future, with reliance on future capital raises.
- Numerous risks are highlighted, including the ongoing impact of the COVID-19 pandemic on clinical trials and operations, manufacturing complexities, regulatory uncertainties, and intense competition from other vaccine developers.
- The company is investing in building sales, marketing, and distribution capabilities for potential commercialization, despite having no prior experience in these areas.
- Moderna continues to advance a broad pipeline of 21 development candidates across various therapeutic areas, underscoring its commitment to mRNA technology beyond COVID-19.
- The filing emphasizes the novel nature of mRNA technology, noting that no mRNA drug has been approved to date, which introduces significant clinical development and regulatory risks.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q3 FY2020, Moderna, Inc. lost $1.48.
- Revenue$157.0M100.0%
- Cost of revenue$-00.0%
- Gross profit$157.0M100.0%
- Operating costs−$392.0M249.7%
- Operating income−$235.0M149.7%
- Interest, other & tax$2.0M1.3%
- Net income−$233.0M148.4%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2020filed October 30, 2020Financial Statements
Q3 FY2020 against Q3 FY2019
| Line item | Q3 FY2020Q3 FY2019 | Change |
|---|---|---|
| Revenue | $157.00M$17.05M | +821.0% |
| Cost of Revenue | $0— | — |
| Gross Profit | $157.00M— | — |
| R&D Expenses | $344.00M$119.64M | +187.5% |
| Operating Expenses | $392.00M$147.81M | +165.2% |
| Operating Income | -$235.00M-$130.76M | −79.7% |
| Net Income | -$233.00M-$123.22M | −89.1% |
| EPS (Basic) | $-0.59$-0.37 | −59.5% |
| EPS (Diluted) | $-0.59— | — |
| Shares Outstanding (Basic) | 395.00M330.77M | +19.4% |
| Shares Outstanding (Diluted) | 395.00M— | — |
05—Questions
Frequently Asked Questions
What is Moderna's current financial position and outlook?
As of September 30, 2020, Moderna had approximately $3.97 billion in cash, cash equivalents, and investments, which is expected to be sufficient to fund operations for at least the next 12 months. However, the company has a history of significant net losses and anticipates incurring continued losses for the foreseeable future. Future funding will likely come from equity or debt financings, government funding, or strategic alliances.
What are the major risks Moderna is facing, especially concerning mRNA-1273?
Moderna faces numerous risks, including the potential for delays in clinical trials due to the COVID-19 pandemic, challenges in scaling up manufacturing, obtaining regulatory approvals, and intense competition from other vaccine developers. There's also the inherent risk associated with developing a novel class of medicine (mRNA) for which no drug has yet been approved. The success of mRNA-1273 is not guaranteed, and its development is subject to the completion of required clinical trials and regulatory approvals.
How is Moderna preparing for the potential commercialization of its products, particularly mRNA-1273?
Moderna is investing in building its sales, marketing, and distribution capabilities, as well as other non-technical infrastructure, in anticipation of the potential commercialization of mRNA-1273 and other future products. This is a new area for the company, as it has no prior experience in these commercial functions. The company may also enter into strategic alliances to leverage the marketing and distribution expertise of other entities.
What is the status of Moderna's broader pipeline beyond mRNA-1273?
Moderna is advancing a pipeline of 21 development candidates across various therapeutic areas, with 13 already in clinical studies. While mRNA-1273 is a primary focus, the company is committed to its broader mRNA platform and continues to invest in research and development for other indications, despite the significant resources dedicated to the COVID-19 vaccine candidate.
06—Continue